The biopharmaceutical CMO and CRO market was exceeded US$ 29.1 billion in 2020 and is projected to reach US$ 59.4 billion by 2030, expanding at an annual CAGR of 7.4 percent, according to a 2021 study by Precedence Research, the Canada-based market Insight Company. The report contains 150+ pages with detailed analysis.
The base year for the study has been considered 2021, the historic year 2019 and 2020, the forecast period considered is from 2021 to 2030. The dairy products market is analyzed on the basis of value (US$ Million), volume (Unit), and price (US$/Unit).
The biopharmaceutical CMO and CRO is an integral part of the biopharmaceutical industry. The CMO and CRO are directly linked and influenced by the biopharmaceutical industry. CMO stands for contract manufacturing organizations that sets up manufacturing plants and produces biopharmaceutical products on large scale on contract basis. These organizations are manufacturing specialists that saves cost and time of the contractor and provides efficient output.
The CRO refers to the contract research organizations that undertake the task of various research and developmental activities assigned by the contractors and helps in the development of new and innovative drugs. The rising demand for the biopharmaceutical drugs among the consumers has contributed to the rapid growth of the biopharmaceutical industry. Biopharmaceutical is rapidly growing globally and it alone accounts for over 20% of the total pharmaceutical industry. Growing investments and manufacturing contracts by the small and medium sized pharma industry players is propelling the growth of the CMO and CRO in the market significantly.
Download Free Sample Copy with TOC, Graphs & List of Figures @ https://www.precedenceresearch.com/sample/1289
Market Report Scope
| Report Highlights | Details |
| Market Size | USD 59.4 Billion by 2030 |
| Growth Rate | CAGR of 7.4% From 2021 to 2030 |
| Base Year | 2020 |
| Historic Data | 2017 to 2020 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Product, Source, Service |
Competition Landscape
In the final section of the research report, Precedence Research provided the global biopharmaceutical CMO and CRO market structure and a detailed competition landscape to provide a dashboard view of key players operating in the biopharmaceutical CMO and CRO market along with their business strategies to report audiences. This section is primarily designed to provide clients with an objective and detailed comparative assessment of the key providers specific to a market segment in the value chain of the market.
Some of the major players in the biopharmaceutical CMO and CRO market include:
- Lonza
- JRS Pharma
- Samsung Biologics
- CMC Biologics
- TOYOBO Co. Ltd.
- RentschlerBiotechnologie
- FUJIFILM Diosynth Biotechnologies
- WuXi Biologics
- Patheon
- BoehringerIngelheim
- PRA Health Sciences
- LabCorp
Crucial factors accountable for market growth are:
- Rapidly growing biopharmaceutical industry
- Rising demand for the biopharmaceutical products
- Increased participation of medium and small-sized enterprises in biologics
- Growing government expenditure on building sophisticated healthcare infrastructure
- Increasing adoption of biopharma drugs and therapeutics
- Rising burden of diseases amongst the population
- Presence of numerous CMOs and CROs in the market
Report Highlights
- By service, the contract manufacturing segment led the global biopharmaceutical CMO and CRO market with remarkable revenue share in 2020. This is attributed to the growing participation of the small and medium conventional pharmaceutical developers in the biopharmaceutical industry owing to its market attractiveness.
- By source, the mammalian segment led the global biopharmaceutical CMO and CRO market with remarkable revenue share in 2020. This is attributed to the growing importance of biotherapies namely, monoclonal antibodies, vaccines, and blood factors are developed using mammalian cell culture. Moreover, the antibody products are the dominant commercial products that foster the segment growth.
- By product type, the biologics segment led the global biopharmaceutical CMO and CRO market with remarkable revenue share in 2020. Biologics gained traction when it opened up the opportunities for the treatment of cancer. Moreover, higher approval rate of biologic medicines is fostering its adoption at a rapid pace among the consumers.
Market Drivers
The global biopharmaceutical CMO and CRO market is primarily driven by the increasing popularity and increasing investments by the key players in the biopharmaceutical industry for the development of cost-effective and innovative drugs.
Restraints
The lack of proper healthcare infrastructure in the underdeveloped economies, lack of awareness regarding technologically advance biopharma products, and high costs involved are the major factors that may hamper the market growth.
Opportunities
The growing research and development activities carried on by the key market players to develop effective drugs and medicines for various serious illnesses and disease like cancer may open up new opportunities in the upcoming future.
Challenges
Lack of adequate capital in the hands of the small pharmaceutical developers who have interests in shifting towards the biopharmaceuticals is a major challenge that may slow down the growth of the global biopharmaceutical CMO and CRO market.
Recent Developments
- In May 2019, Samsung Biologics entered into a contract with GI Innovation for development of Immunochemotherapy. Under this contract, Samsung Biologics will develop a new drug through a combination of protein drugs and human micro-organisms.
Market Segmentation
By Service
- Contract Manufacturing
- Process Development
- Upstream
- Downstream
- Fill & Finish Operations
- Analytical & QC studies
- Packaging
- Process Development
- Contract Research
- Inflammation & Immunology
- Cardiology
- Oncology
- Neuroscience
- Others
By Source
- Mammalian
- Non-Mammalian
By Product
- Biologics
- Vaccines
- Monoclonal antibodies (MABs)
- Recombinant Proteins
- Antisense, RNAi, & Molecular Therapy
- Others
- Biosimilars
Regional Segmentation
– North America (U.S. and Canada)
– Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
– Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
– Latin America (Brazil and Rest of Latin America)
– Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)
Research Methodology
Secondary Research
It involves company databases such as Hoover’s: This assists us recognize financial information, structure of the market participants and industry competitive landscape.
The secondary research sources referred in the process are as follows:
- Governmental bodies, and organizations creating economic policies
- National and international social welfare institutions
- Company websites, financial reports and SEC filings, broker and investor reports
- Related patent and regulatory databases
- Statistical databases and market reports
- Corporate Presentations, news, press release, and specification sheet of Manufacturers
Primary Research
Primary research includes face-to face interviews, online surveys, and telephonic interviews.
- Means of primary research: Email interactions, telephonic discussions and
Questionnaire based research etc.
- In order to validate our research findings and analysis we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.
Most Asked Questions –
- What was the market size value of the biopharmaceutical CMO and CRO in 2020?
- What is the expected market size by 2030?
- What is the biopharmaceutical CMO and CRO market growth?
- What are the key factors that positively influence market growth?
- Who are the prominent players in the biopharmaceutical CMO and CRO market?
Why should you invest in this report?
If you are aiming to enter the global biopharmaceutical CMO and CRO market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for biopharmaceutical CMO and CRO are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2021-2030, so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
Purchase Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1289
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Source Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Biopharmaceutical CMO and CRO Market, By Product
7.1. Biopharmaceutical CMO and CRO Market, by Product Type, 2021-2030
7.1.1. Biologics (Vaccines, Monoclonal antibodies (MABs), Recombinant Proteins, Others)
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Biosimilars
7.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Biopharmaceutical CMO and CRO Market, By Service
8.1. Biopharmaceutical CMO and CRO Market, by Service, 2021-2030
8.1.1. Contract Manufacturing (Process Development, Fill & Finish Operations, Analytical & QC studies, Packaging)
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Contract Research (Inflammation & Immunology, Cardiology, Oncology, Neuroscience, Others)
8.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Biopharmaceutical CMO and CRO Market, By Source
9.1. Biopharmaceutical CMO and CRO Market, by Source, 2021-2030
9.1.1. Mammalian
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Non-Mammalian
9.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Biopharmaceutical CMO and CRO Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Product (2017-2030)
10.1.2. Market Revenue and Forecast, by Service (2017-2030)
10.1.3. Market Revenue and Forecast, by Source (2017-2030)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.1.4.2. Market Revenue and Forecast, by Service (2017-2030)
10.1.4.3. Market Revenue and Forecast, by Source (2017-2030)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.1.5.2. Market Revenue and Forecast, by Service (2017-2030)
10.1.5.3. Market Revenue and Forecast, by Source (2017-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.2. Market Revenue and Forecast, by Service (2017-2030)
10.2.3. Market Revenue and Forecast, by Source (2017-2030)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.4.2. Market Revenue and Forecast, by Service (2017-2030)
10.2.4.3. Market Revenue and Forecast, by Source (2017-2030)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.5.2. Market Revenue and Forecast, by Service (2017-2030)
10.2.5.3. Market Revenue and Forecast, by Source (2017-2030)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.6.2. Market Revenue and Forecast, by Service (2017-2030)
10.2.6.3. Market Revenue and Forecast, by Source (2017-2030)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.7.2. Market Revenue and Forecast, by Service (2017-2030)
10.2.7.3. Market Revenue and Forecast, by Source (2017-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.2. Market Revenue and Forecast, by Service (2017-2030)
10.3.3. Market Revenue and Forecast, by Source (2017-2030)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.4.2. Market Revenue and Forecast, by Service (2017-2030)
10.3.4.3. Market Revenue and Forecast, by Source (2017-2030)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.5.2. Market Revenue and Forecast, by Service (2017-2030)
10.3.5.3. Market Revenue and Forecast, by Source (2017-2030)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.6.2. Market Revenue and Forecast, by Service (2017-2030)
10.3.6.3. Market Revenue and Forecast, by Source (2017-2030)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.7.2. Market Revenue and Forecast, by Service (2017-2030)
10.3.7.3. Market Revenue and Forecast, by Source (2017-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.2. Market Revenue and Forecast, by Service (2017-2030)
10.4.3. Market Revenue and Forecast, by Source (2017-2030)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.4.2. Market Revenue and Forecast, by Service (2017-2030)
10.4.4.3. Market Revenue and Forecast, by Source (2017-2030)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.5.2. Market Revenue and Forecast, by Service (2017-2030)
10.4.5.3. Market Revenue and Forecast, by Source (2017-2030)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.6.2. Market Revenue and Forecast, by Service (2017-2030)
10.4.6.3. Market Revenue and Forecast, by Source (2017-2030)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.7.2. Market Revenue and Forecast, by Service (2017-2030)
10.4.7.3. Market Revenue and Forecast, by Source (2017-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.5.2. Market Revenue and Forecast, by Service (2017-2030)
10.5.3. Market Revenue and Forecast, by Source (2017-2030)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.5.4.2. Market Revenue and Forecast, by Service (2017-2030)
10.5.4.3. Market Revenue and Forecast, by Source (2017-2030)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.5.5.2. Market Revenue and Forecast, by Service (2017-2030)
10.5.5.3. Market Revenue and Forecast, by Source (2017-2030)
Chapter 11. Company Profiles
11.1. Lonza
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. JRS Pharma
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Samsung Biologics
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. CMC Biologics
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. TOYOBO Co. Ltd.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. RentschlerBiotechnologie
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. FUJIFILM Diosynth Biotechnologies
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. WuXi Biologics
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Patheon
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. BoehringerIngelheim
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
11.11. PRA Health Sciences
11.11.1. Company Overview
11.11.2. Product Offerings
11.11.3. Financial Performance
11.11.4. Recent Initiatives
11.12. LabCorp
11.12.1. Company Overview
11.12.2. Product Offerings
11.12.3. Financial Performance
11.12.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Purchase Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1289
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com